Mosliciguat
Appearance
Clinical data | |
---|---|
Other names | BAY 1237592 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C41H36ClF3N2O5 |
Molar mass | 729.19 g·mol−1 |
3D model (JSmol) | |
| |
|
Mosliciguat (BAY 1237592) is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension.[1][2][3][4]
References
[edit]- ^ El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences. 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002. PMID 36921672. S2CID 257513844.
- ^ Friebe, Andreas; Kraehling, Jan R.; Russwurm, Michael; Sandner, Peter; Schmidtko, Achim (August 2023). "The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report". Naunyn-Schmiedeberg's Archives of Pharmacology. 396 (8): 1669–1686. doi:10.1007/s00210-023-02484-8. PMC 10338386. PMID 37079081.
- ^ Auth, Roger; Klinger, James R. (26 October 2023). "Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension". Expert Opinion on Investigational Drugs. 32 (11): 1025–1042. doi:10.1080/13543784.2023.2274439. PMID 37881882. S2CID 264489242.
- ^ Becker-Pelster, Eva M.; Hahn, Michael G.; Delbeck, Martina; Dietz, Lisa; Hüser, Jörg; Kopf, Johannes; Kraemer, Thomas; Marquardt, Tobias; Mondritzki, Thomas; Nagelschmitz, Johannes; Nikkho, Sylvia M.; Pires, Philippe V.; Tinel, Hanna; Weimann, Gerrit; Wunder, Frank; Sandner, Peter; Schuhmacher, Joachim; Stasch, Johannes-Peter; Truebel, Hubert K. F. (1 October 2022). "Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC". Respiratory Research. 23 (1). doi:10.1186/s12931-022-02189-1. PMC 9526466. PMID 36183104.